Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)

Author(s):
Charehbili, A.; Hamdy, N.A.T.; Smit, V.T.H.B.M. (0000-0003-3730-5652); Kessels, L.; Bochove, A. van; Laarhoven, H.W. van; Putter, H.; Kranenbarg, E.M.K.; Leeuwen-Stok, A.E. van; Hoeven, J.J.M. van der (0000-0003-1117-1959); Velde, C.J.H. van de (0000-0003-0104-1800); Nortier, J.W.R.; Kroep, J.R.; Dutch Breast Canc Res Grp BOOG
Published
2016
Publication type
Article / Letter to editor
Breast cancerNeoadjuvant chemotherapy25-Hydroxy-vitamin DZoledronic acid
Date issued
2016-02-28
Language
English
Is part of
The Breast (2016), Vol. 25, p. 69-74
hdl
1887/106162
doi
10.1016/j.breast.2015.10.005